Skip to main content
TipRanks
Go Ultimate75% OFF

Medtronic (2M6) AI Stock Analysis

9 Followers
DE:2M6

Medtronic

(XETRA:2M6)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Broad-based portfolio growthGrowth across multiple operating units, regions and procedure volumes reduces reliance on any single therapy or market. This breadth supports more durable revenue expansion, gives successful products room to scale, and strengthens Medtronic’s ability to sustain performance through differing healthcare demand cycles.
Negative Factors
Elevated debt and leverageAlthough equity supports a moderate leverage profile, the elevated absolute debt balance can reduce financial flexibility if growth slows or capital costs rise. Debt service and refinancing requirements may compete with investment in innovation, acquisitions and shareholder distributions over the medium term.

Medtronic (2M6) vs. iShares MSCI Germany ETF (EWG)

-30%-20%-10%0%10%20%DE:2M6+5.52%EWG+1.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 127.84B
Dividend Yield
2.70%
Average Volume (3M)
1,625
Price to Earnings (P/E)
24.5
Beta (1Y)
0.30
Revenue Growth
3.13%
EPS Growth
5.28%
Country
Germany
Employees
95,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Medtronic Business Overview & Revenue Model

Company Description

Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients...

Medtronic Earnings Call Summary

Earnings Call Date:Sep 01, 2026(Q1-2027)|% Change Since:18.98%|Next Earnings Date:Nov 24, 2026
Earnings Call SentimentPositive

The call was strongly positive. Medtronic reported broad-based revenue and earnings outperformance, significant growth in Cardiac Ablation Solutions, continued momentum in CRM, CST, Surgical, Pelvic Health and Diabetes, improved operating metrics, stronger cash conversion and raised fiscal 2027 guidance. The principal challenges were business-mix pressure on gross margin, neuromodulation softness, low-single-digit Structural Heart growth, expected moderation in some growth rates, and foreign exchange and tariff headwinds.

Positive Updates

Strong First-Quarter Financial Performance
Fiscal 2027 first-quarter revenue was $9.8 billion and adjusted EPS was $1.45, both well ahead of expectations. Organic revenue growth was 13.7%. Excluding the extra selling week, Medtronic delivered its strongest quarterly performance in nearly 8 years, excluding COVID comps.

Negative Updates

Unfavorable Business Mix Impacted Gross Margin
Business mix was unfavorable by 50 basis points, largely reflecting the Diabetes and Cardiac Ablation Solutions businesses. Management said the near-term capital mix continues to impact gross margin.

Company Guidance

For fiscal year '27, Medtronic raised organic revenue growth guidance to 7.25% to 7.75% and expects roughly 6% organic revenue growth in Q2; foreign exchange is expected to be a roughly $50 million to $150 million headwind for the full year and an approximate $25 million to $75 million headwind in 2Q. The company expects operating profit to grow approximately 10%, with operating margin expanding approximately 50 basis points year-over-year, and raised fiscal '27 EPS guidance to $5.94 to $6, with Q2 EPS expected in the range of $1.32 to $1.34 and a roughly neutral impact from foreign exchange. CAS is expected to grow 2.5x the market for the full year and north of 3x the market in Q2, with the market in the mid-teens; Hugo is expected to surpass 50,000 completed procedures by the end of the fiscal year with procedure growth continuing at more than twice the market rate, while the transradial catheter remains on track to launch in the second half of this fiscal year, Neurovascular is expected to reach mid-single digit growth in the back half of the year, ACM is expected to normalize as Medtronic moves through 2027, acquisitions are expected to contribute over $150 million to inorganic growth in fiscal year '27, and the MiniMed separation is intended to close prior to fiscal year-end.

Medtronic Risk Analysis

Medtronic disclosed 34 risk factors in its most recent earnings report. Medtronic reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Medtronic Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:2M6 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
EWEW76Outperform$59.73B57.549.69%―13.44%-26.83%
SYKSYK75Outperform$119.19B32.8015.61%1.14%7.87%22.82%
DXCMDXCM73Outperform$29.91B30.6336.50%―13.03%40.88%
ABTABT67Neutral$179.90B38.159.11%2.45%10.00%-66.06%
BSXBSX64Neutral$62.31B17.7113.87%―8.88%25.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%DE:2M6ABTBSXDXCMEWSYKDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:2M6 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:2M6Medtronic92.446.097.05%
ABTAbbott Laboratories103.00-21.11-17.01%
BSXBoston Scientific41.98-56.06-57.18%
DXCMDexcom79.3217.1127.50%
EWEdwards Lifesciences Corp.101.8517.1420.23%
SYKStryker Corp310.00-56.16-15.34%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.